Interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6) serum levels in kidney allograft patients.

MALAN BOREL I; GARCIA MI; RACCA A; SOUTULLO A; GAITE L

Estocolmo - Suecia

Congreso; 11th International Congress of Immunology; 2001

IUIS - SSI

Objectives: The aims of this work was to determine the dynamic and diagnostic relevance of IL-6 in kidney renal allograft. Methods: IL-6 and sIL-6 serum levels were determined by ELISA test in 45 kidney allograft recipients, 13 with acute (AR), 15 with chronic graft (CR) dysfunction and 11 with stable graft evolution (SE) and in 10 healthy volunteers as controls (C). Results: IL-6 and sIL-6R from AR and CR patients were both higher than C (P=0.005) IL-6: 11.09±2.80pg/ml (AR), 14.26±2.11pg/ml (CR), 0.26±0.04pg/ml (C); sIL-6R: 44615.76±3347.72pg/ml (AR), 31545.49±5842.95pg/ml (CR), 19241.41±622.72pg/ml (C). No differences were observed between IL-6 in SE and C patients (P=0,738). sIL-6R levels were higher in SE than C (P=0,03). The IL-6 serum levels were evaluated at the beginning of RA and 10 months following. At this time baseline levels of IL-6 were observed when the patients with RA had a good evolution (P=0.005) and higher if they evolved to CR (P=0.03). In those with RC, IL-6 levels were increase according to renal dysfunction (P=0.03). Conclusions: IL-6 but not sIL-6R serum levels could be useful marker for indicating the kidney allograft evolution.